echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Circulation: SGLT2 inhibitors reduce the risk of hyperkalemia in patients with type 2 diabetes

    Circulation: SGLT2 inhibitors reduce the risk of hyperkalemia in patients with type 2 diabetes

    • Last Update: 2022-05-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hyperkalemia increases the risk of arrhythmias and death, and limits the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs)


    This study is a meta-analysis of routine monitoring of serum potassium levels in randomized, double-blind, placebo-controlled randomized trials of SGLT2 inhibitors in high cardiovascular risk patients with type 2 diabetes with and without CKD.


    Defined as central laboratory-determined serum potassium ≥6.



    A total of 49,875 subjects were included.



    SGLT2 inhibitors do not increase the risk of hypokalemia SGLT2 inhibitors do not increase the risk of hypokalemia

    In conclusion, the use of SGLT2 inhibitors reduces the risk of severe hyperkalemia without increasing the risk of hypokalemia in patients with type 2 diabetes at high cardiovascular risk, with or without chronic kidney disease


    The use of SGLT2 inhibitors reduces the risk of severe hyperkalemia without increasing the risk of hypokalemia in patients with type 2 diabetes at high cardiovascular risk, with or without CKD


    Original source:

    Original Source: Original Source:

    Neuen Brendon L,Oshima Megumi,Agarwal Rajiv et al.


    Neuen Brendon L,Oshima Megumi,Agarwal Rajiv et al.
    Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.
    [J] .
    Circulation, 2022, https://doi.
    org/10.
    1161/CIRCULATIONAHA.
    121.
    057736.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.